BSX vs ZBH
BSX and ZBH side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BSXBOSTON SCIENTIFIC CORPORATION | ZBHZIMMER BIOMET HOLDINGS, INC. |
|---|---|---|
| Market cap | $60.82B | $18.03B |
| P/E (TTM) | 17.0 | 22.9 |
| P/B | 2.44 | 1.43 |
| P/S | 3.0x | 2.2x |
| Dividend yield | — | 1.06% |
| Revenue | $21.00B(TTM) | $8.51B(TTM) |
| Revenue growth (YoY) | 19.9% | 7.2% |
| Net income | $3.67B(TTM) | $806.70M(TTM) |
| Earnings growth (YoY) | 56.7% | -22.0% |
| EPS, diluted | $2.47(TTM) | $4.12(TTM) |
| EBIT margin | 18.0% | 13.3% |
| ROE | 11.6% | 5.6% |
| ROIC | 10.0% | 5.0% |
| Piotroski F | 8/9 | 6/9 |
| 1y total return | -58.3% | -4.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: BSX frente a ZBH
| Métrica | BSX | ZBH |
|---|---|---|
| Valor final | $18.2K | $8.6K |
| Retorno total | +82.3% | -13.6% |
| CAGR | +6.0% | -1.4% |
| Volatilidad | 27.5% | 28.6% |
| Sharpe | 0.20 | -0.05 |
| Sortino | 0.27 | -0.07 |
| Caída máxima | -61.5% | -53.5% |
Basado en 2600 días de negociación comunes, 2016-06-29 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)